A5049384875- Hematopoietic Stem Cell Transplantation
- T-cell and Retrovirus Studies
- Lymphoma Diagnosis and Treatment
- Vector-Borne Animal Diseases
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Animal Disease Management and Epidemiology
- Transplantation: Methods and Outcomes
- Mesenchymal stem cell research
- RNA Research and Splicing
- Polyomavirus and related diseases
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Microbial Applications in Construction Materials
- CNS Lymphoma Diagnosis and Treatment
- Blood groups and transfusion
- Nuclear Structure and Function
- Renal Transplantation Outcomes and Treatments
- Cancer Genomics and Diagnostics
- Organ and Tissue Transplantation Research
Presbyterian Hospital
2015-2024
New York Hospital Queens
2015-2024
NewYork–Presbyterian Hospital
2015-2024
Cornell University
2015-2024
Weill Cornell Medicine
2018-2024
Palmetto Hematology Oncology
2020
Montana State University
2018-2020
Morristown Medical Center
2017
Columbia University Irving Medical Center
2009-2016
Columbia University
2007-2015
Adult T-cell leukemia-lymphoma (ATL) is a distinct mature malignancy caused by chronic infection with human T-lymphotropic virus type 1 diverse clinical features and prognosis. ATL remains challenging disease as result of its features, multidrug resistance malignant cells, frequent large tumor burden, hypercalcemia, and/or opportunistic infection. In 2009, we published consensus report to define prognostic factors, subclassifications, treatment strategies, response criteria. The 2009 has...
Using the United States Surveillance, Epidemiology and End Results (SEER) 17 dataset, we examined incidence survival patterns for patients with cutaneous T-cell lymphomas (CTCLs) diagnosed following institution of World Health Organization–European Organisation Research Treatment Cancer (WHO-EORTC) classification. From 2005 to 2008, 2273 cases CTCL were diagnosed. The age-adjusted rate per 100 000 person-years mycosis fungoides (MF) was 0.55 Sézary syndrome (SS) 0.01. Incidence higher among...
Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety mogamulizumab ATL patients with acute, lymphoma, chronic subtypes relapsed/refractory, aggressive disease US, Europe, Latin America. With stratification by subtype, were randomized 2:1 to intravenous 1.0 mg/kg once weekly weeks biweekly thereafter...
Abstract Richter syndrome (RS) represents a transformation from chronic lymphocytic leukemia/small lymphoma (CLL/SLL) to aggressive lymphoma, most commonly diffuse large B-cell (DLBCL), which is associated with dismal prognosis. Patients DLBCL-RS have poor outcomes DLBCL-directed therapy; thus, consolidation hematopoietic cell transplantation (HCT) has been used, durable remissions observed. Studies reporting HCT in patients small, not evaluated the prognostic impact of cytogenetic risk...
Abstract Background Levofloxacin prophylaxis is recommended to prevent gram-negative bloodstream infections (BSIs) in patients with prolonged chemotherapy-induced neutropenia. However, increasing fluoroquinolone resistance may decrease the effectiveness of this approach. Methods We assessed prevalence colonization fluoroquinolone-resistant Enterobacterales (FQRE) among admitted for hematopoietic cell transplantation (HCT) from November 2016 August 2019 and compared risk BSI between...
Autologous hematopoietic cell transplantation (auto-HCT) has long been the standard approach for patients with relapsed/refractory (R/R) chemosensitive diffuse large B lymphoma (DLBCL). However, advent of chimeric antigen receptor (CAR) T therapy caused a paradigm shift in management R/R DLBCL patients, especially recent approval CD19-directed CAR-T second-line setting high-risk groups (primary refractory and early relapse [≤12 months]). Consensus on contemporary role, optimal timing,...
Abstract Exportin-1 (XPO1), the main soluble nuclear export receptor in eukaryotic cells, is frequently overexpressed diffuse large B-cell lymphoma (DLBCL). A selective XPO1 inhibitor, selinexor, received approval as single agent for relapsed or refractory (R/R) DLBCL. Elucidating mechanisms by which overexpression supports cancer cells could facilitate further clinical development of inhibitors. We uncovered here that increases tolerance to genotoxic stress, leading a poor response...
Abstract BACKGROUND: To define the clinicopathologic and prognostic features of patients with human T‐cell lymphotropic virus type‐1 (HTLV‐1)‐associated adult leukemia/lymphoma (ATLL) in North America, standard criteria were used to identify ATLL. METHODS: Statistical analyses included descriptive statistics, Kaplan‐Meir survival analysis, recursive partitioning. RESULTS: Eighty‐nine identified between August 1992 May 2007, including 37 (41.6%) males 52 (58.4%) females a median age 50 years...
Background: Nearly 10% of immigrants to the United States come from Caribbean region. In this paper, we analyzed incidence and mortality rates major cancers in Bahamas, Barbados, Cuba, Dominican Republic, Haiti, Jamaica, Puerto Rico, Trinidad Tobago, compared them with US patterns. Methods: We obtained age-standardized, sex-specific cancer for bladder, breast, cervix, esophagus, large bowel, liver, lung, pancreas, prostate, stomach 8 countries GLOBOCAN program International Agency Research...
Epstein-Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD) are common potentially fatal complications after allogeneic transplantation with mismatched donors T-cell depletion. Haplo-cord combines a UCB graft third-party cells. Conditioning involves thymoglobulin. EBV PTLD were in initial patients. As of March 2017, we administered prophylactic dose rituximab 375 mg/m2 pre-transplant. Among 147 patients who did not receive rituximab, the cumulative...
Covid-19 vaccination is recommended in allogeneic transplant recipients, but many questions remain regarding its efficacy. Here we studied serologic responses 145 patients who had undergone transplantation using vivo T-cell depletion. Median age was 57 (range 21-79) at and 61 24-80) vaccination. Sixty-nine percent were Caucasian. One third each received transplants from HLA-identical related (MRD), adult unrelated (MUD), or haploidentical-cord blood donors. Graft-versus-host disease (GVHD)...
BACKGROUND An increased risk of non‐Hodgkin lymphoma (NHL) has been observed among individuals with occupational exposure to benzene, but the those living near benzene release sites not well described. METHODS To investigate spatial patterns NHL incidence and association between distance sites, authors linked geocoded data on in Georgia from 1988 1998 using Environmental Protection Agency's (EPA) Toxics Release Inventory (TRI), census tract level population statistics, Comprehensive Cancer...
Reduced-intensity conditioning (RIC) regimens, improved HLA matching, and better supportive care allow allogeneic stem cell transplant (alloSCT) to be offered older patients. Only a small percentage of eligible patients between ages 65 74 years actually undergo alloSCT, comprehensive outcome data from the aging population are still lacking. We examined who underwent alloSCT using melphalan-based RIC for hematologic malignancies at our institution. identified 125 than (median, 69; range, 66...
Haplo-cord stem cell transplantation combines the infusion of CD34 selected hematopoietic progenitors from a haplo-identical donor with an umbilical cord blood (UCB) graft unrelated and allows faster count recovery, low rates disease recurrence chronic graft-versus-host (GVHD). But contribution to long-term transplant outcome remains unclear. We analyzed 39 recipients haplo-cord transplants acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), engrafted in remission at 2 months....
Hairy cell leukaemia (HCL) is a rare type of B-cell non-Hodgkin lymphoma (B-NHL), which not known to be associated with any characteristic recurrent karyotypic abnormality. A recent study that used massively parallel whole exome sequencing identified an activating V600E mutation in BRAF, appeared specific for HCL. Here, we confirm the specificity BRAF HCL among low and intermediate grade B-NHL describe real-time polymerase chain reaction method detecting this cases tumour burden. The does...
Limited studies have reported on outcomes for lymphoid malignancy patients receiving alternative donor allogeneic stem cell transplants. We previously described combining CD34-selected haploidentical grafts with umbilical cord blood (haplo-cord) to accelerate neutrophil and platelet engraftment. Here, we examine the outcome of malignancies undergoing haplo-cord transplantation at University Chicago Weill Cornell Medical College. analyzed 42 lymphoma chronic lymphoblastic leukemia (CLL) who...
Donor-specific HLA antibodies (DSAs) have been associated with an increased risk of graft failure. To decrease DSA levels and reduce the failure in haploidentical cord blood transplantation recipients, we studied effect bortezomib (BTZ) i.v. immune globulin (IVIG) pretransplantation. Between 2012 2016, 14 patients a level >2000 mean fluorescence intensity (MFI) to 1 or more mismatched alleles donors, both were treated BTZ IVIG. Fourteen received median 4 doses (range, 2 8 doses) 1.3 mg/m2...
Preliminary evidence indicates that the addition of low-dose total body irradiation (TBI) (2-4 Gy) to reduced intensity conditioning may reduce rate relapse in allogeneic stem cell transplants. In very high-risk patients receiving combination haploidentical single-unit cord blood transplants, we have added 4 Gy TBI widely used fludarabine, melphalan regimen, hopes reducing and decreasing graft rejection.We retrospectively reviewed posttransplant outcomes who underwent haplocord transplant...